Longboat Amniotics have discovered a novel, unique cell present in full term amniotic fluid. This neonatal cell carries the characteristic properties of mesenchymal stem cells. These combined features indicate that the cell is well suited for mesenchymal stem cell (MSC) based therapy with an elevated chance of success in treatment.
Encouraged by these findings, we have developed a patent protected eco-system for the safe retrieval, processing, typing, cataloguing and bio banking of these cells. Once the eco system is fully certified our goal is to become an international provider of high quality, top performing stem cells for research and therapy development. Many MSC based therapies are already in development, and as they become available we will be ready to offer the best possible cell material for these.
We invite everyone interested in our endeavours to follow our progress – sign up for our newsletter and get a glimpse of what is coming next!